Last reviewed · How we verify
NCT05141123
Registry of Patients Treated by Preloaded Fenestrated Stent-graft Designs for Complex Endovascular Aortic Procedures
trial testing Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for in Renal Aneurysm in 741 participants. Completed in 20 April 2023.
20 April 2023
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 741 |
| Start date | 30 October 2022 |
| Primary completion | 20 April 2023 |
| Estimated completion | 20 April 2023 |
| Sites | 19 locations across Denmark, France, Italy, Sweden, United Kingdom, Germany, United States, Spain |
Drugs / interventions tested
- Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for
Conditions studied
- Renal Aneurysm — all drugs for Renal Aneurysm →
- Aneurysm Thoracic — all drugs for Aneurysm Thoracic →
- Aneurysm Abdominal — all drugs for Aneurysm Abdominal →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
18 and older, any sex, with Renal Aneurysm or Aneurysm Thoracic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms. Results and postoperative events are reported in accordance with the current reporting standards for endovascular aortic repair prepared and revised by the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of The Society for Vascular Surgery/American Association for Vascular Surgery. The Registry will include approximately 300 patients treated from January 2015 to May 2021 (retrospective arm) and June 2021 to June 2023 (perspective arm) for the routine treatment of para-renal and thoraco-abdominal aneurysms. To reach 300 patients, the enrollments can be extended until June 2026.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05141123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05141123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 1 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05141123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing